Joo Hyun Soo, Jang Jae Young, Eun Soo Hoon, Kim Sang Kyun, Jung In Seop, Ryu Chang Beom, Kim Young Seok, Kim Jin Oh, Cho Joo Young, Kim Yun Soo, Lee Joon Seong, Lee Moon Sung, Shim Chan Sup, Kim Boo Sung
Institute for Digestive Research, Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea.
Korean J Gastroenterol. 2007 May;49(5):320-6.
BACKGROUND/AIMS: Gastric variceal bleeding is an infrequent but serious complication of portal hypertension. Endoscopic injection of Histoacryl (N-butyl-2-cyanoacrylate) has been approved as an effective treatment for gastric variceal bleeding. The aim of this study was to evaluate the long-term efficacy and safety of the endoscopic injection of Histoacryl for the treatment of gastric varices.
Between January 1994 and January 2005, eighty-five patients with gastric varices received endoscopic injections of Histoacryl. Among these 85 patients, 65 received the procedure within 1 week after gastric variceal bleeding, and 13 received as a prophylactic procedure. According to the Sarin classification, 32 patients were GOV1 and 53 were GOV2. Most of the varices were large (F2 or F3, 75 patients). The average volume of Histoacryl per each session was 1.43 ml. Among 85 patients, 72 patients were followed-up and the median duration was 24.5 months.
The rate of initial hemostasis was 98.6% and recurrent bleeding occurred in 29.2% (21 of 72). When rebleeding occurred, 76.2% was within 1 year after the initial injection. Treatment failure-related mortality rate was 1.4% (1 of 85). Twenty-seven patients died, mostly due to hepatocelluar carcinoma or liver failure. Two patients experienced pulmonary embolism and one experienced splenic infarction. They recovered without specific treatment. Rebleeding rate had a tendency to increase in patients with hepatocelluar carcinoma (p=0.051) and GOV2 (p=0.061).
Histoacryl injection therapy is a effective treatment method for gastric varices with high initial hemostasis rate and low major complications.
背景/目的:胃静脉曲张出血是门静脉高压症一种不常见但严重的并发症。内镜下注射组织黏合剂(N-丁基-2-氰基丙烯酸酯)已被批准作为治疗胃静脉曲张出血的有效方法。本研究旨在评估内镜下注射组织黏合剂治疗胃静脉曲张的长期疗效和安全性。
1994年1月至2005年1月期间,85例胃静脉曲张患者接受了内镜下组织黏合剂注射治疗。在这85例患者中,65例在胃静脉曲张出血后1周内接受了该治疗,13例作为预防性治疗。根据萨林分类法,32例为GOV1型,53例为GOV2型。大多数静脉曲张为大型(F2或F3级,75例)。每次注射组织黏合剂的平均量为1.43毫升。85例患者中,72例接受了随访,中位随访时间为24.5个月。
初始止血率为98.6%,29.2%(72例中的21例)出现再出血。再出血发生时,76.2%发生在首次注射后1年内。治疗失败相关死亡率为1.4%(85例中的1例)。27例患者死亡,主要原因是肝细胞癌或肝功能衰竭。2例发生肺栓塞,1例发生脾梗死。他们未经特殊治疗而康复。肝细胞癌患者(p=0.051)和GOV2型患者(p=0.061)的再出血率有增加趋势。
组织黏合剂注射治疗是一种治疗胃静脉曲张的有效方法,初始止血率高,主要并发症发生率低。